SG10201704745UA - Novel compounds and compositions for targeting cancer stem cells - Google Patents
Novel compounds and compositions for targeting cancer stem cellsInfo
- Publication number
- SG10201704745UA SG10201704745UA SG10201704745UA SG10201704745UA SG10201704745UA SG 10201704745U A SG10201704745U A SG 10201704745UA SG 10201704745U A SG10201704745U A SG 10201704745UA SG 10201704745U A SG10201704745U A SG 10201704745UA SG 10201704745U A SG10201704745U A SG 10201704745UA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- stem cells
- novel compounds
- cancer stem
- targeting cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31589010P | 2010-03-19 | 2010-03-19 | |
| US31588610P | 2010-03-19 | 2010-03-19 | |
| US32581410P | 2010-04-19 | 2010-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201704745UA true SG10201704745UA (en) | 2017-07-28 |
Family
ID=50940329
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201502079VA SG10201502079VA (en) | 2010-03-19 | 2011-03-21 | Novel compounds and compositions for targeting cancer stem cells |
| SG10201704745UA SG10201704745UA (en) | 2010-03-19 | 2011-03-21 | Novel compounds and compositions for targeting cancer stem cells |
| SG10201706265PA SG10201706265PA (en) | 2010-03-19 | 2011-03-21 | Novel compounds and compositions for targeting cancer stem cells |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201502079VA SG10201502079VA (en) | 2010-03-19 | 2011-03-21 | Novel compounds and compositions for targeting cancer stem cells |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201706265PA SG10201706265PA (en) | 2010-03-19 | 2011-03-21 | Novel compounds and compositions for targeting cancer stem cells |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP3295796A1 (en) |
| JP (11) | JP2014098049A (en) |
| CN (4) | CN107311969B (en) |
| CA (3) | CA2959931A1 (en) |
| DK (1) | DK3108750T3 (en) |
| ES (1) | ES2689928T3 (en) |
| NZ (2) | NZ712826A (en) |
| RU (2) | RU2657750C1 (en) |
| SG (3) | SG10201502079VA (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2194987T3 (en) | 2007-09-10 | 2016-08-15 | Boston Biomedical Inc | Newly known group of stat3 signaling pathway inhibitors and cancer stem cell inhibitors |
| EP2547205B1 (en) * | 2010-03-19 | 2024-03-20 | 1Globe Biomedical Co., Ltd. | Novel methods for targeting cancer stem cells |
| CN107311969B (en) * | 2010-03-19 | 2022-01-28 | 北京强新生物科技有限公司 | Novel compounds and compositions for targeting cancer stem cells |
| KR20150139955A (en) | 2013-04-09 | 2015-12-14 | 보스톤 바이오메디칼, 인크. | 2-acetylnaphtho[2,3-b]furan-4,9-dione for use on treating cancer |
| EA201792623A1 (en) * | 2015-06-03 | 2018-04-30 | Бостон Биомедикал, Инк. | COMPOSITIONS CONTAINING CANCER STEM BONE INHIBITOR AND IMMUNOTHERAPEUTIC AGENT TO BE USED IN CANCER TREATMENT |
| GB201515391D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| GB201515387D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| JP6751658B2 (en) | 2016-11-15 | 2020-09-09 | クラリオン株式会社 | Voice recognition device, voice recognition system |
| CA3045306A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| JP2020520923A (en) | 2017-05-17 | 2020-07-16 | ボストン バイオメディカル， インコーポレイテッド | Methods for treating cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61205257A (en) * | 1985-03-08 | 1986-09-11 | Ishihara Sangyo Kaisha Ltd | Benzoylurea compound, production thereof, and anticancer drug containing same |
| EP0945131A1 (en) * | 1998-03-27 | 1999-09-29 | Boehringer Ingelheim Pharma KG | Peroral drug suspension |
| JP2003525862A (en) * | 1999-01-27 | 2003-09-02 | ザ ユニヴァーシティー オブ サウス フロリダ | Inhibition of STAT3 signaling for treatment of human cancer |
| WO2004026253A2 (en) * | 2002-09-17 | 2004-04-01 | Arqule, Inc. | Novel lapacho compounds and methods of use thereof |
| CL2003002353A1 (en) * | 2002-11-15 | 2005-02-04 | Vertex Pharma | COMPOUNDS DERIVED FROM DIAMINOTRIAZOLS, INHIBITORS D ELA PROTEINA QUINASA; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE; AND ITS USE OF THE COMPOUND IN THE TREATMENT OF DISEASES OF ALLERGIC DISORDERS, PROLIFERATION, AUTOIMMUNES, CONDIC |
| EP1849830B1 (en) * | 2005-01-28 | 2012-02-29 | Takeda Pharmaceutical Company Limited | Finely divided composition containing poorly water soluble substance |
| JP2006290871A (en) * | 2005-03-16 | 2006-10-26 | Taheebo Japan Kk | Compound exhibiting anti-cancer property, intermediate therefor and method for producing the same |
| WO2007041479A2 (en) * | 2005-09-30 | 2007-04-12 | Smithkline Beecham Corporation | Pharmaceutical compositions |
| EP1860126A1 (en) * | 2006-05-26 | 2007-11-28 | INEOS Manufacturing Belgium NV | Polyolefin powder |
| DK2194987T3 (en) | 2007-09-10 | 2016-08-15 | Boston Biomedical Inc | Newly known group of stat3 signaling pathway inhibitors and cancer stem cell inhibitors |
| AU2009267683B2 (en) * | 2008-07-08 | 2014-04-03 | Beta Pharma, Inc. | Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof |
| NZ602328A (en) * | 2010-03-19 | 2014-11-28 | Boston Biomedical Inc | Novel compounds and compositions for targeting cancer stem cells |
| CN107311969B (en) * | 2010-03-19 | 2022-01-28 | 北京强新生物科技有限公司 | Novel compounds and compositions for targeting cancer stem cells |
| EP2547205B1 (en) * | 2010-03-19 | 2024-03-20 | 1Globe Biomedical Co., Ltd. | Novel methods for targeting cancer stem cells |
-
2011
- 2011-03-21 CN CN201710613672.3A patent/CN107311969B/en active Active
- 2011-03-21 CN CN201710134235.3A patent/CN106860443A/en active Pending
- 2011-03-21 NZ NZ712826A patent/NZ712826A/en unknown
- 2011-03-21 EP EP17196754.0A patent/EP3295796A1/en active Pending
- 2011-03-21 CN CN201410101861.9A patent/CN104016951B/en active Active
- 2011-03-21 SG SG10201502079VA patent/SG10201502079VA/en unknown
- 2011-03-21 RU RU2016123004A patent/RU2657750C1/en active
- 2011-03-21 CN CN201710665153.1A patent/CN107721958A/en active Pending
- 2011-03-21 SG SG10201704745UA patent/SG10201704745UA/en unknown
- 2011-03-21 RU RU2015142279A patent/RU2015142279A/en not_active Application Discontinuation
- 2011-03-21 DK DK16182813.2T patent/DK3108750T3/en active
- 2011-03-21 CA CA2959931A patent/CA2959931A1/en not_active Abandoned
- 2011-03-21 EP EP16182813.2A patent/EP3108750B1/en active Active
- 2011-03-21 CA CA2993363A patent/CA2993363A1/en not_active Abandoned
- 2011-03-21 NZ NZ701237A patent/NZ701237A/en unknown
- 2011-03-21 CA CA2959951A patent/CA2959951A1/en not_active Abandoned
- 2011-03-21 SG SG10201706265PA patent/SG10201706265PA/en unknown
- 2011-03-21 ES ES16182813.2T patent/ES2689928T3/en active Active
-
2014
- 2014-03-03 JP JP2014040226A patent/JP2014098049A/en not_active Withdrawn
- 2014-03-03 JP JP2014040227A patent/JP2014098050A/en not_active Withdrawn
- 2014-03-03 JP JP2014040225A patent/JP5993390B2/en not_active Expired - Fee Related
-
2015
- 2015-02-25 JP JP2015035285A patent/JP2015098489A/en active Pending
- 2015-09-11 JP JP2015179115A patent/JP6246169B2/en not_active Expired - Fee Related
-
2016
- 2016-09-30 JP JP2016194176A patent/JP2016222723A/en not_active Withdrawn
-
2017
- 2017-10-13 JP JP2017199380A patent/JP2018002744A/en not_active Withdrawn
-
2018
- 2018-04-20 JP JP2018081329A patent/JP2018115209A/en not_active Withdrawn
-
2020
- 2020-01-31 JP JP2020014705A patent/JP2020063308A/en not_active Withdrawn
- 2020-05-08 JP JP2020082479A patent/JP2020114888A/en active Pending
-
2021
- 2021-12-06 JP JP2021197732A patent/JP2022020002A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2547334A4 (en) | Novel compounds and compositions for targeting cancer stem cells | |
| HK1243746A1 (en) | Compositions | |
| EP2547205A4 (en) | Novel methods for targeting cancer stem cells | |
| HK1178797A1 (en) | Sunblock composition | |
| EP2593098A4 (en) | Methods and compositions for cancer immunotherapy | |
| SG10201502079VA (en) | Novel compounds and compositions for targeting cancer stem cells | |
| GB201002983D0 (en) | Nutritinal composition | |
| GB201009549D0 (en) | Compositions | |
| GB201119596D0 (en) | Improved compositions | |
| GB201009546D0 (en) | Compositions | |
| GB201010954D0 (en) | Compositions | |
| GB201002861D0 (en) | Compositions | |
| EP2625231A4 (en) | Ink-printable compositions | |
| EP2771014A4 (en) | Pharmaceutical composition for elimination of cancer stem cells | |
| WO2011116344A9 (en) | Targeting cancer stem cells | |
| IL214545A0 (en) | Compositions and methods for visualizing and eliminating cancer stem cells | |
| SI2534242T1 (en) | Improved composition for inhibiting tumor cell proliferation | |
| IL225952A0 (en) | Pharmaceitucal compositions | |
| GB201014591D0 (en) | Compositions | |
| GB201005927D0 (en) | Improved composition | |
| GB201007790D0 (en) | Compositions | |
| GB201004717D0 (en) | Composition | |
| EP2575743A4 (en) | Antiperspirant compositions | |
| GB201006175D0 (en) | Composition | |
| PL2545016T3 (en) | Composition including hemipotassium phosphate |